HRAS

Kura Oncology Appoints Teresa Bair as Chief Legal Officer

Retrieved on: 
Monday, October 18, 2021
Breakthrough therapy, HNSCC, Tipifarnib, Administration, Bowling Green State University, Cancer, Fortune 500, University, Nasdaq, Senior, State university system, AML, Trustee, Risk, HRAS, NDA, Â, Corporation, Harris Beach, Genomics, University at Buffalo School of Engineering and Applied Sciences, Security (finance), Law, Therapy, Central Waqf Council, FDA, Data analysis, Patient, News, Business administration, Board, GLOBE, KMT2A, U.S. Securities and Exchange Commission, KURA, SAN, Company, NPM1, Drug development, Safety, State University of New York Upstate Medical University, Research, Hand, General counsel, Pharmaceutical industry, Management

SAN DIEGO, Oct. 18, 2021 (GLOBE NEWSWIRE) -- Kura Oncology, Inc. (Nasdaq: KURA), a clinical-stage biopharmaceutical company committed to realizing the promise of precision medicines for the treatment of cancer, today announced the appointment of Teresa Bair as Chief Legal Officer and Corporate Secretary.

Key Points: 
  • SAN DIEGO, Oct. 18, 2021 (GLOBE NEWSWIRE) -- Kura Oncology, Inc. (Nasdaq: KURA), a clinical-stage biopharmaceutical company committed to realizing the promise of precision medicines for the treatment of cancer, today announced the appointment of Teresa Bair as Chief Legal Officer and Corporate Secretary.
  • Ms. Bair joins Kura with more than 25 years of combined in-house and law firm experience, most recently as General Counsel at Athenex.
  • On behalf of our board and senior leadership team, we want to extend a warm welcome to Teresa, said Troy Wilson, Ph.D., J.D., President and Chief Executive Officer of Kura Oncology.
  • Ms. Bair joins Kura from Athenex, where she served most recently as General Counsel and Senior Vice President, Administration.

Erasca Announces First Patient Dosed in HERKULES-2 Phase 1b/2 Lung Cancer Master Protocol Evaluating ERAS-007 in Multiple Combinations

Retrieved on: 
Thursday, September 9, 2021

As the foundation of Erascas lung cancer platform, HERKULES-2 is a master protocol designed to inhibit multiple oncogenic drivers of the RAS/MAPK pathway to address high unmet needs in lung cancer.

Key Points: 
  • As the foundation of Erascas lung cancer platform, HERKULES-2 is a master protocol designed to inhibit multiple oncogenic drivers of the RAS/MAPK pathway to address high unmet needs in lung cancer.
  • ERAS-007, a potential best-in-class inhibitor of the extracellular signal-regulated kinases (ERK), targets the terminal node of the RAS/MAPK pathway.
  • We are a clinical-stage precision oncology company singularly focused on discovering, developing, and commercializing therapies for patients with RAS/MAPK pathway-driven cancers.
  • Erasca cautions you that statements contained in this press release regarding matters that are not historical facts are forward-looking statements.

Kura Oncology to Participate in Two Upcoming Investor Conferences

Retrieved on: 
Tuesday, September 7, 2021

ET / 4:00 a.m. PT on September 13, 2021; and

Key Points: 
  • ET / 4:00 a.m. PT on September 13, 2021; and
    A pre-recorded fireside chat at the Cantor Global Healthcare Conference, available at 3:20 p.m.
  • Kura Oncology is a clinical-stage biopharmaceutical company committed to realizing the promise of precision medicines for the treatment of cancer.
  • In addition, Kura is pursuing the use of tipifarnib in combination with other oncology therapeutics to address larger genetic subsets of patients, including those who have HRAS- and/or PIK3CA-dependent HNSCC.
  • For additional information about Kura, please visit the Companys website at www.kuraoncology.com .

Kura Oncology Reports Second Quarter 2021 Financial Results

Retrieved on: 
Thursday, August 5, 2021
Company, Acute leukemia, Research, Head and neck cancer, U.S. Securities and Exchange Commission, Investment, Webcast, Chief medical informatics officer, Amgen, Acquisition, Novartis, NPM1, Acute myeloid leukemia, Kura (music producer), AML, Patient, Equity capital markets, IND, KMT2A, Pharmacokinetics, 5, Wells Fargo, Therapy, GLOBE, HRAS, Cancer, News, Mixed-phenotype acute leukemia, Myelodysplastic syndrome, Risk, Hand, Nasdaq, Breakthrough therapy, Safety, Head, Tipifarnib, Security (finance), Pharmaceutical industry, Lithium, Animal

ET

Key Points: 
  • ET
    SAN DIEGO, Aug. 05, 2021 (GLOBE NEWSWIRE) -- Kura Oncology, Inc. (Nasdaq: KURA), a clinical-stage biopharmaceutical company committed to realizing the promise of precision medicines for the treatment of cancer, today reported second quarter 2021 financial results and provided a corporate update.
  • Research and development expenses for the second quarter of 2021 were $21.1 million, compared to $13.7 million for the second quarter of 2020.
  • General and administrative expenses for the second quarter of 2021 were $12.6 million, compared to $7.5 million for the second quarter of 2020.
  • Net loss for the second quarter of 2021 was $33.7 million, compared to a net loss of $20.5 million for the second quarter of 2020.

Kura Oncology to Participate in Wedbush PacGrow Healthcare Virtual Conference

Retrieved on: 
Wednesday, August 4, 2021
Life sciences, Biotechnology, Articles, Specialty drugs, Kura, Biopharmaceutical, Precision medicine, Oncology

SAN DIEGO, Aug. 04, 2021 (GLOBE NEWSWIRE) -- Kura Oncology, Inc. (Nasdaq: KURA), a clinical-stage biopharmaceutical company committed to realizing the promise of precision medicines for the treatment of cancer, today announced its participation in the Wedbush PacGrow Healthcare Virtual Conference.

Key Points: 
  • SAN DIEGO, Aug. 04, 2021 (GLOBE NEWSWIRE) -- Kura Oncology, Inc. (Nasdaq: KURA), a clinical-stage biopharmaceutical company committed to realizing the promise of precision medicines for the treatment of cancer, today announced its participation in the Wedbush PacGrow Healthcare Virtual Conference.
  • Troy Wilson, Ph.D., J.D., President and Chief Executive Officer, is scheduled to participate in a panel titled Bullseye - Targeted Oncology Part 2 at 10:20 a.m.
  • Kura Oncologyis a clinical-stage biopharmaceutical company committed to realizing the promise of precision medicines for the treatment of cancer.
  • For additional information about Kura, please visit the Companys website at www.kuraoncology.com .

Kura Oncology Announces Clinical Collaboration to Evaluate Tipifarnib in Combination with Alpelisib in Head and Neck Squamous Cell Carcinoma

Retrieved on: 
Tuesday, July 6, 2021
Drugs, Health, Orphan drugs, Chloroarenes, Imidazoles, Tipifarnib, Farnesyltransferase inhibitor, Oncology, Head and neck cancer, Ras GTPase, Squamous cell carcinoma, HRAS

Tipifarnib is Kuras farnesyl transferase inhibitor drug candidate currently in a registration-directed trial as a monotherapy in patients with HRAS mutant HNSCC.

Key Points: 
  • Tipifarnib is Kuras farnesyl transferase inhibitor drug candidate currently in a registration-directed trial as a monotherapy in patients with HRAS mutant HNSCC.
  • Combining tipifarnib with alpelisib has the potential to provide a clinically meaningful increase in anti-tumor activity compared to when inhibiting either pathway alone, said Stephen Dale, M.D., Chief Medical Officer of Kura Oncology.
  • We believe this clinical collaboration will enable us to potentially expand the use of tipifarnib to a significantly higher percentage of patients with advanced HNSCC.
  • Head and neck squamous cell carcinoma (HNSCC) is the seventh most common cancer worldwide, accounting for more than 500,000 new cases each year.

Kura Oncology Announces Publication of Tipifarnib Phase 2 Data in Journal of Clinical Oncology

Retrieved on: 
Monday, March 22, 2021
Drugs, Orphan drugs, Chloroarenes, Imidazoles, Tipifarnib, HRAS, Head and neck cancer

The paper, titled Tipifarnib in Head and Neck Squamous Cell Carcinoma with HRAS Mutations, was published online in the Journal of Clinical Oncology earlier today.

Key Points: 
  • The paper, titled Tipifarnib in Head and Neck Squamous Cell Carcinoma with HRAS Mutations, was published online in the Journal of Clinical Oncology earlier today.
  • These data also reinforce the relevance of genomic testing for HRAS mutations to identify patients who could potentially benefit from tipifarnib treatment.
  • "We are pleased to see our data from the Phase 2 RUN-HN trial of tipifarnib published in the Journal of Clinical Oncology for review by the broader clinical community, said Troy Wilson, Ph.D., J.D., President and Chief Executive Officer of Kura Oncology.
  • In addition to HNSCC, tipifarnib has demonstrated encouraging clinical activity in multiple additional genetically defined tumor types.

Kura Oncology Reports Overall Survival Data from Phase 2 Trial of Tipifarnib in HRAS Mutant Head and Neck Squamous Cell Carcinoma

Retrieved on: 
Friday, May 29, 2020
HRAS, Tipifarnib, Head and neck cancer, Ras GTPase, Branches of biology, Health, Chemistry

At data cutoff, 21 patients with HRAS mutant HNSCC were enrolled1, of whom 18 were evaluable for efficacy.

Key Points: 
  • At data cutoff, 21 patients with HRAS mutant HNSCC were enrolled1, of whom 18 were evaluable for efficacy.
  • In addition to updated clinical outcome data in patients with HRAS mutant HNSCC, Kura also reported compelling single-agent activity in tumors of the salivary gland and urothelial carcinoma with HRAS mutations.
  • Tipifarnib has been granted Fast Track designation by the U.S. Food and Drug Administration for the treatment of patients with HRAS mutant HNSCC.
  • Such forward-looking statements include statements regarding, among other things, the efficacy, safety and therapeutic potential of Kuras product candidate tipifarnib.

Kura Oncology Announces Three Abstracts Accepted for Presentation at ASCO20 Virtual Scientific Program

Retrieved on: 
Wednesday, May 13, 2020
Chloroarenes, Imidazoles, Tipifarnib, HRAS, Ras GTPase, Chemistry

We are pleased to announce the presentation of three clinical abstracts for tipifarnib, including an oral presentation highlighting single-agent activity in multiple solid tumors with HRAS mutations, said Troy Wilson, Ph.D., J.D., President and Chief Executive Officer of Kura Oncology.

Key Points: 
  • We are pleased to announce the presentation of three clinical abstracts for tipifarnib, including an oral presentation highlighting single-agent activity in multiple solid tumors with HRAS mutations, said Troy Wilson, Ph.D., J.D., President and Chief Executive Officer of Kura Oncology.
  • Tipifarnib, is a potent, selective and orally bioavailable inhibitor of farnesyl transferase in-licensed from Janssen in December 2014.
  • Kura has received multiple issued patents for tipifarnib, providing patent exclusivity in the U.S. and foreign countries.
  • Kura Oncology is a clinical-stage biopharmaceutical company committed to realizing the promise of precision medicines for the treatment of cancer.

GeneTex Launches Novel Recombinant RAS (G12D Mutant) Antibody [HL10]

Retrieved on: 
Thursday, February 20, 2020
Branches of biology, Biology, Biochemistry, Immunology, Glycoproteins, KRAS, Antibody, Neuroblastoma RAS viral oncogene homolog, HRAS, Reagent, Ras GTPase

IRVINE, Calif., Feb. 20, 2020 /PRNewswire/ --GeneTex, a research antibody manufacturing company, is proud to announce the release of a novel recombinant rabbit monoclonal RAS (G12D mutant) antibody [HL10].

Key Points: 
  • IRVINE, Calif., Feb. 20, 2020 /PRNewswire/ --GeneTex, a research antibody manufacturing company, is proud to announce the release of a novel recombinant rabbit monoclonal RAS (G12D mutant) antibody [HL10].
  • The human RAS proteins (i.e., KRAS, HRAS, and NRAS) have been recognized for decades as some of the most potent triggers of malignancies.
  • As Alexander Ball, M.D., Senior Scientist at GeneTex, comments, "Many cancer researchers have refocused on conquering RAS, and this recombinant rabbit RAS (G12D) antibody [HL10] is exactly the type of reagent to facilitate their efforts."
  • The release of GeneTex's recombinant rabbit monoclonal RAS (G12D mutant) antibody [HL10](GTX635362) marks the fully operational status of GeneTex's state-of-the-art recombinant antibody manufacturing facility and the continued evolution of GeneTex as a major developer and supplier of quality, rigorously validated antibody reagents that deliver reproducible performance.